Improved removal of viruslike particles from purified monoclonal antibody igm preparation via virus filtration

Nature Biotechnology

Volumn 14, Issue 5, 1996, Pages 651-652

  Maerz, Holger ^a   Hahn, Sven Oliver ^a,b   Maassen, Anke ^b   Meisel, Helga ^b   Roggenbuck, Dirk ^c   Sato, Tetsuo ^d   Tanzmann, Heinz ^b   Emmrich, Frank ^a   Marx, Uwe ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c Dr Fooke Laboratorien GmbH   (Germany)

^d Asahi Chemical Industries   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN M; MONOCLONAL ANTIBODY;

AGAR GEL ELECTROPHORESIS; ANTIBODY STRUCTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FILTER; FILTRATION; HEPATITIS B VIRUS; IMMUNOBLOTTING; IMMUNOGLOBULIN STRUCTURE; PRIORITY JOURNAL; PURIFICATION; REVIEW; VIRUS PARTICLE;

HEPATITIS B VIRUS;

EID: 0029865081     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt0596-651     Document Type: Article

References (20)

1. Nicklas, W., Kraft, V., Meyer, B. 1993. Contamination of transplantable tumors, cell-lines and monoclonal antibodies with rodent viruses. Lab. Anim. Sci. 43:296-300.
2. Minor, P. 1993. Virological aspects of the quality control of human monoclonal antibodies, International Association of the Biological Standardization, Developments in biological standardization, S. Karger AG, Basel:233-236
3. Trijzelaar, B. 1993. Regulatory affairs and biotechnology in Europe. III. Introduction into good regulatory practice: Validation of virus removal and inactivation. Biotherapy 6:93-102
4. Frommer, W. et al. 1993. Safe biotechnology (5). Recommendations for safe work with animal and human cell cultures concerning potential human pathogens. Appl. Microbiol. Biotechnol. 39:141-147
5. EEC Regulatory Document—Note for guidance—Validation of virus removal and inactivation procedures. 1991. Biologicals 19:247-251
6. Webster, R.G. and Granoff, A., 1994. Encyclopedia of virology: Vol. 1-3. Academic Press, London
7. Tateishi, J et al. 1993. Removal of causative agent of Creutzfeldt-Jakob-disease (CJD) through membrane filtration method. Membrane 18:357-362.
8. Prusiner, S.B. 1982. Novel proteinaceous infectious particles cause scrapie. Science 216:136-144.
9. Roitt, I.M., Brostoff, J., Male, D.K. 1991. Kurzes Lehrbuch der Immunologie. Georg Thieme Verlag, Stuttgart.
10. DiLeo, A.J. and Allegrezza, A.E. 1991. Validatable virus removal from protein solutions. Nature 351:420-421.
11. Tsurumi, T., Osawa, N., Hitaka, H., and Hirasaki, T. 1990. Structure of cuprammonium regenerated cellulose hollow fiber (BMM hollow fiber) for virus removal. Polym. J. 22:751-758.
12. White, E.M., Grun, J.B., Sun, C.-S., and Sito, A.F. 1991. Process validation for virus removal and inactivation. Reprinted from Biopharm.
13. Hamamoto, Y. et al. 1989. A novel method for removal of human immunodeficiency virus: Filtration with porous polymeric membranes. Vox Sang 56:230-236
14. Tsuboi, T. et al. 1992. Combination of virus removal and inactivation for the process validation of bio-drugs. Murakami, H., Shirahata, S., Tachibana, H., Animal cell technology: Basic and applied aspects, Kluwer Academic Publishers, Dordrecht:289-294.
15. Burnouf-Radosevich, M., Appourchaux, P., Huart, J.J., and Burnouf, T. 1994. Nanofiltration, a new specific virus elimination method applied to high-purity factor IX and factor XI concentrates. Vox Sang. 67:132-138.
16. Manabe, S. et al. 1991. Elimination of microorganisms from cell culture medium using regenerated cellulose hollow fiber (BMM). Sasaki, R. & Ikura, K., Animal Cell Culture and Production of Biologicals, Kluwer Academic Publishers, Dordrecht: 87-94.
17. Tomokiyo, K. et al. 1991. Studies on virus elimination and inactivation effects of highly purified factor VIII concentrates. Jpn. Clin. Rep. 25:1-8.
18. Sekiguchi, S. et al. 1989. Possibility of hepatitis B virus removal from human plasma using regenerated cellulose hollow fiber (BMM). Membrane 14:77-83.
19. Yasua, T. et al. 1991. The particle size of hepatitis C virus estimated by filtration through microporous regenerated cellulose fibre. J. Gen. Virolog. 72:2021-2024.
20. EC note for guidance: Validation of virus removal and inactivation procedures. 1991. Pharmacol. Toxicol. 69:144-148.